MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

Overview ForecastFinancials Chart Transcripts

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 11.88% institutional investors, 9.68% insiders, and 78.44% retail investors. Bvf inc/il is the largest institutional shareholder, holding 24.82% of MLTX shares. Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund, with 1.65% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	MoonLake Immunotherapeutics	11.88%	9.68%	78.44%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bvf inc/il	16.00M	24.82%	$298.26M
Deep track capital, lp	6.41M	9.94%	$119.46M
Cormorant asset management, lp	4.48M	6.95%	$83.52M
Janus henderson group	3.45M	5.35%	$64.30M
D. e. shaw	2.39M	3.71%	$44.56M
Avoro capital advisors	2.00M	3.16%	$14.34M
Bioimpact capital	1.81M	2.81%	$33.76M
Weiss asset management lp	1.71M	2.65%	$31.84M
Adage capital partners gp	1.50M	2.37%	$10.76M
Logos global management lp	1.50M	2.33%	$27.96M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Bvf inc/il	16.00M	9.50%	$298.26M
Lion point capital, lp	67.50K	7.52%	$1.26M
Cormorant asset management, lp	4.48M	4.19%	$83.52M
Ghost tree capital	300.00K	4.13%	$13.19M
Bioimpact capital	1.81M	2.61%	$33.76M
Acuta capital partners	191.76K	2.52%	$3.57M
Great point partners	500.00K	2.14%	$9.32M
Exome asset management	215.38K	2.08%	$4.01M
Deep track capital, lp	6.41M	1.95%	$119.46M
Vivo capital	1.00M	1.56%	$18.64M

Top Buyers

Holder	Shares	% Assets	Change
Bioimpact capital	1.81M	2.61%	1.81M
Deep track capital, lp	6.41M	1.95%	1.80M
Adage capital partners gp	1.50M	0.02%	1.50M
Weiss asset management lp	1.71M	0.54%	1.38M
Janus henderson group	3.45M	0.03%	1.36M

Top Sellers

Holder	Shares	% Assets	Change
Bvf inc/il	16.00M	9.50%	-3.75M
Avoro capital advisors	2.00M	0.19%	-2.15M
Westfield capital management co lp	-	-	-1.26M
Federated hermes	-	-	-1.25M
Jane street group	453.63K	0.00%	-1.23M

New Positions

Holder	Shares	% Assets	Change	Value
Bioimpact capital	1.81M	2.61%	1.81M	$33.76M
Adage capital partners gp	1.50M	0.02%	1.50M	$10.76M
Holocene advisors, lp	600.00K	0.03%	600.00K	$11.18M
Great point partners	500.00K	2.14%	500.00K	$9.32M
Casdin capital	450.00K	0.64%	450.00K	$8.39M

Sold Out

Holder	Change
Ifp advisors	-1.00
National bank of canada /fi/	-2.00
Wpg advisers	-3.00
True wealth design	-5.00
Gamma investing	-6.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	78	-46.21%	7,657,293	-86.41%	11	0.15%	41	-58.16%	25	-10.71%
Dec 31, 2025	17	-90.17%	854,269	-97.72%	1	0.04%	13	-85.71%	3	-93.33%
Sep 30, 2025	30	-79.31%	901,952	-98.46%	1	0.02%	17	-73.02%	9	-83.64%
Jun 30, 2025	145	-2.03%	58,588,368	-0.85%	92	1.06%	63	-11.27%	54	25.58%
Mar 31, 2025	150	19.05%	59,722,976	-5.57%	94	0.93%	72	-	43	43.33%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Jupiter Merian Glb Eq AbsRet I USD Acc	1.18M	1.65%	1.18M
Polar Capital Biotech S Inc	1.00M	1.58%	-
Fidelity Growth Compy Commingled Pl S	981.02K	1.54%	273.63K
T. Rowe Price Health Sciences	1.00M	1.40%	253.67K
Fidelity Growth Company Fund	740.92K	1.17%	248.13K
Federated Hermes Kaufmann Growth	665.00K	1.05%	-
Federated Hermes Kaufmann R	665.00K	1.05%	-
US Small-Cap Growth II Equity Comp	523.89K	0.83%	-134.19K
Fidelity Select Health Care	520.00K	0.82%	-150.00K
Federated Hermes Kaufmann Small Cap A	503.00K	0.79%	-16.00K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 11, 2026	Bodenstedt Matthias	Chief Financial Officer	Sell	$273.33K
Apr 14, 2026	Bodenstedt Matthias	Chief Financial Officer	Sell	$47.45K
Apr 13, 2026	Santos da Silva Jorge	Chief Executive Officer	Sell	$945.64K
Apr 10, 2026	Santos da Silva Jorge	Chief Executive Officer	Sell	$1.81M
Apr 09, 2026	Bodenstedt Matthias	Chief Financial Officer	Sell	$1.63M

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	6
2026 Q1	-	3
2025 Q4	1	4
2025 Q3	-	6
2025 Q2	-	-

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 11.88%, followed by 9.68% insiders and 78.44% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 35.75%, which MoonLake Immunotherapeutics falls below.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (16M shares, 24.82%), Deep track capital, lp (6.41M shares, 9.94%), and Cormorant asset management, lp (4.48M shares, 6.95%). Together, they hold 41.71% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 9.50% of its assets in 16M MoonLake Immunotherapeutics shares, valued at 298.26M$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 1.65% of its total shares outstanding invested in 1.18M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools